Pfizer Total Common and Preferred Stock Dividends Paid 2010-2024 | PFE
Pfizer annual/quarterly total common and preferred stock dividends paid history and growth rate from 2010 to 2024. Total common and preferred stock dividends paid can be defined as the cash outflow for all company dividends paid out to preferred and common shareholders.
- Pfizer total common and preferred stock dividends paid for the quarter ending December 31, 2024 were $-9.512B, a 2.87% increase year-over-year.
- Pfizer total common and preferred stock dividends paid for the twelve months ending December 31, 2024 were $-23.768B, a 2.89% increase year-over-year.
- Pfizer annual total common and preferred stock dividends paid for 2024 were $-9.512B, a 2.87% increase from 2023.
- Pfizer annual total common and preferred stock dividends paid for 2023 were $-9.247B, a 2.94% increase from 2022.
- Pfizer annual total common and preferred stock dividends paid for 2022 were $-8.983B, a 2.91% increase from 2021.
Pfizer Annual Total Common and Preferred Stock Dividends Paid
(Millions of US $) |
| 2024 |
$-9,512 |
| 2023 |
$-9,247 |
| 2022 |
$-8,983 |
| 2021 |
$-8,729 |
| 2020 |
$-8,440 |
| 2019 |
$-8,043 |
| 2018 |
$-7,978 |
| 2017 |
$-7,659 |
| 2016 |
$-7,317 |
| 2015 |
$-6,940 |
| 2014 |
$-6,609 |
| 2013 |
$-6,580 |
| 2012 |
$-6,534 |
| 2011 |
$-6,234 |
| 2010 |
$-6,088 |
| 2009 |
$-5,548 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$151.025B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
